Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
A Prospective Randomized, Multi-center Study to Assess the Safety and Efficacy of Mucosta (Rebamipide), in Combination With Omeprazole as Adjuvant Therapy in Gastric Ulcer Patients
A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.
open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
Inclusion Criteria: Patients with dyspepsia or epigastric pain and endoscopically proven gastric and duodenal ulcers Required laboratory parameters and time limits (screening blood tests will be taken including hemoglobin, white blood cell count, random glucose, potassium, sodium, chlorine, creatinine, AST, ALT, bilirubin, and alkaline phosphatase) Age > 18 years A statement that all patients must have signed an informed consent form prior to registration in study Exclusion Criteria: Patients who had undergone surgery for ulcers History of hypersensitivity to drugs to be used in the study Women who are pregnant or lactating or intended to get pregnant during the study period